All data are based on the daily closing price as of October 8, 2025
t
Tanvex BioPharma
6541.TW
1.73 USD
0.01
+0.58%
Overview
Last close
1.73 usd
Market cap
456.88M usd
52 week high
2.50 usd
52 week low
1.15 usd
Target price
1.71 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
126.3523
Price/Book Value
2.8501
Enterprise Value
485.82M usd
EV/Revenue
133.8492
EV/EBITDA
-9.0582
Key financials
Revenue TTM
3.63M usd
Gross Profit TTM
-870601.7 usd
EBITDA TTM
-37.60M usd
Earnings per Share
-0.23 usd
Dividend
N/A usd
Total assets
235.90M usd
Net debt
N/A usd
About
Tanvex BioPharma, Inc., a biopharmaceutical company, researches, develops, manufactures, and sells biosimilar products in Taiwan and the United States. It focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company's products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial. The company was formerly known as Ruenvex Biotech, Inc. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.